Background. Gastrinomas are rare functional neuroendocrine tumors causing the Zollinger-Ellison syndrome (ZES). At presentation, up to 25% of gastrinomas are metastasized, predominantly to the liver. Embolization of liver metastases might reduce symptoms of ZES although a postembolization syndrome can occur. In this study, the results of embolization are presented, and the literature results are described. Methods. From a prospective database of pancreatic neuroendocrine tumors, all patients with liver metastatic gastrinomas were selected if treated with arterial embolization. Primary outcome parameters were symptom reduction, complications, and response rate. The literature search was performed with these items. Results. Three patients were identified; two presented with synchronous liver metastases. All the three patients had symptoms of ZES before embolization. Postembolization syndrome occurred in two patients. Six months after embolization, all the 3 patients had a clinical and complete radiological response; a biochemical response was seen in 2/3 patients. From the literature, only a small number of gastrinoma patients treated with liver embolization for liver metastases were found, and similar results were described. Conclusion. Selective liver embolization is an effective and safe therapy for the treatment of liver metastatic gastrinomas in the reduction of ZES. Individual treatment strategies must be made for the optimal success rate. 1. Introduction Gastrinomas are neuroendocrine tumors (NET), primarily located in the duodenum or pancreas. Gastrinomas are by definition functional tumors secreting gastrin. Gastrin overproduction causes the Zollinger-Ellison syndrome, which includes ulceration of the gastrointestinal tract, mainly the jejunum, resulting in abdominal pain and diarrhea [1]. The incidence of gastrinomas is 0.5–2 per million per year and therefore very rare [2, 3]. Gastrinomas are classified according to a grading system, similar to other pancreatic neuroendocrine tumors (pNETs). This grading is based on histopathology and subdivided into immunostaining for tumor markers and proliferation markers (Table 1) [4]. Using the current WHO criteria, grades 1 and 2 are well-differentiated pNETs with increased expression of the tumor markers, chromogranin A, and synaptophysin. Grade 3 tumors are poorly differentiated with areas of necrosis and decreased expression of chromogranin A [3, 5]. Table 1: Tumor grade of gastrinomas based on proliferation markers [ 4]. Up to 25% of the gastrinomas are diagnosed when metastases are already present,
References
[1]
R. M. Zollinger and E. H. Ellison, “Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas,” Annals of Surgery, vol. 142, pp. 709–723, 1955.
[2]
R. T. Jensen, B. Niederle, and E. Mitry, “Frascati consensus conference, European neuroendocrine tumor society, gastrinoma (duodenal and pancreatic),” Neuroendocrinology, vol. 84, no. 3, pp. 173–182, 2006.
[3]
R. T. Jensen, G. Cadiot, M. L. Brandi et al., “ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes,” Neuroendocrinology, vol. 95, no. 2, pp. 98–119, 2012.
[4]
G. Rindi, G. Kl？ppel, H. Alhman et al., “TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system,” Virchows Archiv, vol. 449, no. 4, pp. 395–401, 2006.
[5]
P. Komminoth, A. Perren, K. Oberg, G. Rindi, G. Kloppel, and P. U. Heitz, “Gastrinoma,” in Pathology and Genetics: Tumors of the Endocrine Organs, R. A. DeLellis, R. Lloyd, P. U. Heitz, and C. Eng, Eds., pp. 191–194, WHO Classification of Tumors, IARC Press, Lyon, France, 2004.
[6]
H. C. Weber, D. J. Venzon, J.-T. Lin et al., “Determinants of metastatic rate and survival in patients with Zollinger- Ellison syndrome: a prospective long-term study,” Gastroenterology, vol. 108, no. 6, pp. 1637–1649, 1995.
[7]
J. R. Strosberg, A. Cheema, and L. K. Kvols, “A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract,” Cancer Control, vol. 18, no. 2, pp. 127–137, 2011.
[8]
R. P. Riemsma, M. M. Bala, R. Wolff, and J. Kleijnen, “Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases,” The Cochrane Database of Systematic Reviews, no. 9, Article ID CD009498, 2012.
[9]
S. Dhand and R. Gupta, “Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome,” Seminars in Interventional Radiology, vol. 28, no. 2, pp. 207–211, 2011.
[10]
F. Yinglu, L. Changquan, Z. Xiaofeng, L. Bai, Z. Dezeng, and C. Zhe, “A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization,” Journal of Alternative and Complementary Medicine, vol. 15, no. 2, pp. 175–181, 2009.
[11]
E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009.
[12]
J. J. Atema, R. Amri, O. R. Busch, E. A. Rauws, D. J. Gouma, and E. J. Nieveen van Dijkum, “Surgical treatment of gastrinomas: a single-centre experience,” HPB, vol. 14, no. 12, pp. 833–838, 2012.
[13]
T. Sato, K. Konishi, H. Kimura et al., “Strategy for pancreatic endocrine tumors,” Hepato-Gastroenterology, vol. 47, no. 32, pp. 537–539, 2000.
[14]
H. A. Mitty, R. R. P. Warner, L. H. Newman, J. S. Train, and I. H. Parnes, “Control of carcinoid syndrome with hepatic artery embolization,” Radiology, vol. 155, no. 3, pp. 623–626, 1985.
[15]
P. P. Kamat, S. Gupta, J. E. Ensor et al., “Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases,” CardioVascular and Interventional Radiology, vol. 31, no. 2, pp. 299–307, 2008.
[16]
J. R. Strosberg, J. Choi, A. B. Cantor, and L. K. Kvols, “Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors,” Cancer Control, vol. 13, no. 1, pp. 72–78, 2006.
[17]
V. Meij, J. M. Zuetenhorst, R. van Hillegersberg et al., “Local treatment in unresectable hepatic metastases of carcinoid tumors: experiences with hepatic artery embolization and radiofrequency ablation,” World Journal of Surgical Oncology, vol. 3, article 75, 2005.
[18]
R. S. Chamberlain, D. Canes, K. T. Brown et al., “Hepatic neuroendocrine metastases: does intervention alter outcomes?” Journal of the American College of Surgeons, vol. 190, no. 4, pp. 432–445, 2000.
[19]
R. G. Marlink, J. J. Lokich, J. R. Robins, and M. E. Clouse, “Hepatic arterial embolization for metastatic hormone-secreting tumors,” Technique, Effectiveness, and Complications, Cancer, vol. 65, no. 10, pp. 2227–2232, 1990.
[20]
F. Stockmann, H. J. Von Romatowski, W. V. Reimold, R. Schuster, and W. Creutzfeldt, “Hepatic artery embolization for treatment of endocrine gastrointestinal tumors with liver metastases,” Zeitschrift fur Gastroenterologie, vol. 22, no. 11, pp. 652–660, 1984.
[21]
S. Gupta, M. M. Johnson, R. Murthy et al., “Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival,” Cancer, vol. 104, no. 8, pp. 1590–1602, 2005.
[22]
D. A. Osborne, E. E. Zervos, J. Strosberg et al., “Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors,” Annals of Surgical Oncology, vol. 13, no. 4, pp. 572–581, 2006.
[23]
J. A. Ajani, C. H. Carrasco, C. Charnsangavej, N. A. Samaan, B. Levin, and S. Wallace, “Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization,” Annals of Internal Medicine, vol. 108, no. 3, pp. 340–344, 1988.
[24]
K. T. Brown, B. Y. Koh, L. A. Brody et al., “Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms,” Journal of Vascular and Interventional Radiology, vol. 10, no. 4, pp. 397–403, 1999.
[25]
B. K. Eriksson, E. G. Larsson, B. M. Skogseid, A. M. L？fberg, L. E. L？relius, and K. E. Oberg, “Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors,” Cancer, vol. 83, no. 11, pp. 2293–2301, 1998.
[26]
T. X. Yang, T. C. Chua, and D. L. Morris, “Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases—a systematic review,” Surgical Oncology, vol. 21, no. 4, pp. 299–308, 2012.
[27]
K. A. Yao, M. S. Talamonti, A. Nemcek et al., “Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors,” Surgery, vol. 130, no. 4, pp. 677–685, 2001.
[28]
L. M. Sutherland, J. A. R. Williams, R. T. A. Padbury, D. C. Gotley, B. Stokes, and G. J. Maddern, “Radiofrequency ablation of liver tumors: a systematic review,” Archives of Surgery, vol. 141, no. 2, pp. 181–190, 2006.
[29]
R. Murthy, R. Nunez, J. Szklaruk et al., “Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications,” Radiographics, vol. 25, supplement 1, pp. S41–S55, 2005.
[30]
S. Grozinsky-Glasberg, D. Barak, M. Fraenkel et al., “Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas,” Cancer, vol. 117, no. 7, pp. 1377–1385, 2011.
[31]
H. Oberleithner, C. Riethmüller, T. Ludwig et al., “Differential action of steroid hormones on human endothelium,” Journal of Cell Science, vol. 119, no. 9, pp. 1926–1932, 2006.
[32]
J. Tombran-Tink, N. Lara, S. E. Apricio et al., “Retinoic acid and dexamethasone regulate the expression of PEDF in retinal and endothelial cells,” Experimental Eye Research, vol. 78, no. 5, pp. 945–955, 2004.
